Vistide (Cidofovir) Important Safety Information from Gilead Sciences International Limited as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 05/03/2013

 

Problem Or Issue:
Important Safety Information communication from Gilead Sciences International Limited on product recall leading to a shortage in commercial supply in the EU affecting Vistide (Cidofovir) 75 mg/ml concentrate for solution for infusion.

Important Safety Information - Vistide (Cidofovir) 75 mg/ml concentrate for solution for infusion


« Back